JP2024517695A - 複素環式化合物及び使用方法 - Google Patents

複素環式化合物及び使用方法 Download PDF

Info

Publication number
JP2024517695A
JP2024517695A JP2023565518A JP2023565518A JP2024517695A JP 2024517695 A JP2024517695 A JP 2024517695A JP 2023565518 A JP2023565518 A JP 2023565518A JP 2023565518 A JP2023565518 A JP 2023565518A JP 2024517695 A JP2024517695 A JP 2024517695A
Authority
JP
Japan
Prior art keywords
cancer
diazabicyclo
methoxy
fluorotetrahydro
pyrrolidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023565518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024517695A5 (cg-RX-API-DMAC7.html
Inventor
ランマン,ブライアン
ブルツ,ライアン・ポール
ジャオ,ウェイ
リー,シャオフェン
ヤマノ,マイケル・エム
リー,ユンシャオ
チェン,ニン
ヒューズモーエン,ビアギッテ・バインライヒ
レス-ペーテルゼン,セバスティアン
メディナ,ホセ・エム
リー,カーシュエ
ペタス,リピング
ラヒモフ,レーネ
ナバラトネ,プリマリ・バスンデラ
ルイ,ホワン
モーア,クリストファー・ピー
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2024517695A publication Critical patent/JP2024517695A/ja
Publication of JP2024517695A5 publication Critical patent/JP2024517695A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2023565518A 2021-04-29 2022-04-28 複素環式化合物及び使用方法 Pending JP2024517695A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163181625P 2021-04-29 2021-04-29
US63/181,625 2021-04-29
US202163277309P 2021-11-09 2021-11-09
US63/277,309 2021-11-09
PCT/US2022/026623 WO2022232331A1 (en) 2021-04-29 2022-04-28 Heterocyclic compounds and methods of use

Publications (2)

Publication Number Publication Date
JP2024517695A true JP2024517695A (ja) 2024-04-23
JP2024517695A5 JP2024517695A5 (cg-RX-API-DMAC7.html) 2025-05-08

Family

ID=83847330

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565518A Pending JP2024517695A (ja) 2021-04-29 2022-04-28 複素環式化合物及び使用方法

Country Status (7)

Country Link
US (1) US20250059205A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329757A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024517695A (cg-RX-API-DMAC7.html)
AU (1) AU2022264784A1 (cg-RX-API-DMAC7.html)
CA (1) CA3217856A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023012726A (cg-RX-API-DMAC7.html)
WO (1) WO2022232331A1 (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020020307A2 (pt) 2018-04-04 2021-01-12 Arvinas Operations, Inc. Moduladores de proteólise e métodos de uso associados
CN115141215B (zh) * 2021-03-30 2023-09-15 上海德琪医药科技有限公司 Kras g12d蛋白抑制剂和其用途
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023125627A1 (en) * 2021-12-28 2023-07-06 Lynk Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and application thereof
WO2023138583A1 (zh) * 2022-01-21 2023-07-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
CA3243798A1 (en) 2022-02-09 2023-08-17 Quanta Therapeutics, Inc. Kras Modulators and Their Uses
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023198191A1 (zh) * 2022-04-15 2023-10-19 杭州多域生物技术有限公司 一种六元并六元化合物、制备方法、药物组合物和应用
WO2023230190A1 (en) 2022-05-25 2023-11-30 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
EP4536364A1 (en) 2022-06-10 2025-04-16 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202400600A (zh) * 2022-06-16 2024-01-01 美商昂勝醫療科技股份有限公司 喹唑啉衍生物、其組成物及方法
TW202409051A (zh) 2022-07-27 2024-03-01 大陸商江蘇恆瑞醫藥股份有限公司 稠環類化合物、其製備方法及其在醫藥上的應用
WO2024046370A1 (zh) * 2022-08-30 2024-03-07 上海科州药物研发有限公司 作为kras抑制剂的杂环化合物,及其制备和治疗用途
PE20260006A1 (es) 2023-01-26 2026-01-06 Arvinas Operations Inc Protacs degradadores de kras basados en cereblon y usos relacionados con los mismos
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
CN121487951A (zh) 2023-04-07 2026-02-06 锐新医药公司 大环ras抑制剂
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
AU2024251341A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of a ras inhibitor
EP4695261A1 (en) 2023-04-14 2026-02-18 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
US20250059208A1 (en) * 2023-06-30 2025-02-20 Gilead Sciences, Inc. Kras modulating compounds
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
US20250109147A1 (en) 2023-09-08 2025-04-03 Gilead Sciences, Inc. Kras g12d modulating compounds
CN122374018A (zh) 2023-10-06 2026-07-10 美国安进公司 用于癌症治疗的组合疗法
US20250114346A1 (en) 2023-10-09 2025-04-10 Incyte Corporation Combination therapy using a kras g12d inhibitor and pd-1 inhibitor or pd-l1 inhibitor
KR20260110993A (ko) 2023-10-09 2026-07-14 인사이트 코포레이션 Kras g12d 억제제 및 egfr 억제제를 포함하는 암 치료용 조합
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
US20260137674A1 (en) 2024-10-23 2026-05-21 Incyte Corporation Combination therapy using a kras g12d inhibitor, and a nucleoside analog, and/or a microtubule inhibitor
WO2026090333A1 (en) 2024-10-23 2026-04-30 Incyte Corporation Combination using a kras g12d inhibitor and chemotherapy combinations as well as their use in the treatment of cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
WO2020097537A2 (en) * 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Kras g12d変異に対して阻害活性を有する化合物
JP2023531269A (ja) * 2020-06-30 2023-07-21 インベンティスバイオ カンパニー リミテッド キナゾリン化合物、その製造方法および用途
JP2023540270A (ja) * 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
JP2024506329A (ja) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP2024508755A (ja) * 2021-02-16 2024-02-28 セラス, インコーポレイテッド Krasを阻害するための組成物及び方法
JP2024510207A (ja) * 2021-03-12 2024-03-06 ブリストル-マイヤーズ スクイブ カンパニー Kras阻害剤
JP2024510606A (ja) * 2021-03-12 2024-03-08 ブリストル-マイヤーズ スクイブ カンパニー Kras g12d阻害剤
JP2024517693A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 2-アミノベンゾチアゾール化合物及びその使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104321322A (zh) * 2012-03-30 2015-01-28 理森制药股份公司 作为c-met蛋白激酶调节剂的新型3,5-二取代-3h-咪唑并[4,5-b]吡啶和3,5-二取代-3h-[1,2,3]三唑并[4,5-b]吡啶化合物
US10544099B2 (en) * 2016-05-04 2020-01-28 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US20200352931A1 (en) * 2017-12-12 2020-11-12 Phenex Discovery Verwaltungs-GmbH Oxalamides as modulators of indoleamine 2,3-dioxygenase
CN112110918B (zh) * 2019-06-21 2023-08-22 劲方医药科技(上海)有限公司 螺环取代的嘧啶并环类化合物,其制法与医药上的用途
EP4144732A4 (en) * 2020-04-29 2024-05-01 Shanghai Ringene BioPharma Co., Ltd. BENZOTHIAZOLYL BIARYL COMPOUND, PREPARATION METHOD AND USE THEREOF

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016049568A1 (en) * 2014-09-25 2016-03-31 Araxes Pharma Llc Methods and compositions for inhibition of ras
WO2017172979A1 (en) * 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Krasの共有結合性阻害剤
WO2020097537A2 (en) * 2018-11-09 2020-05-14 Genentech, Inc. Fused ring compounds
WO2021041671A1 (en) * 2019-08-29 2021-03-04 Mirati Therapeutics, Inc. Kras g12d inhibitors
JP2023512113A (ja) * 2019-11-29 2023-03-23 大鵬薬品工業株式会社 Kras g12d変異に対して阻害活性を有する化合物
JP2023531269A (ja) * 2020-06-30 2023-07-21 インベンティスバイオ カンパニー リミテッド キナゾリン化合物、その製造方法および用途
JP2023540270A (ja) * 2020-08-28 2023-09-22 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP2024505594A (ja) * 2021-02-09 2024-02-06 メッドシャイン ディスカバリー インコーポレイテッド ピリミジン芳香環化合物
JP2024506329A (ja) * 2021-02-09 2024-02-13 カムクワット バイオサイエンシーズ インコーポレイテッド 複素環式化合物およびその使用
JP2024508755A (ja) * 2021-02-16 2024-02-28 セラス, インコーポレイテッド Krasを阻害するための組成物及び方法
JP2024510207A (ja) * 2021-03-12 2024-03-06 ブリストル-マイヤーズ スクイブ カンパニー Kras阻害剤
JP2024510606A (ja) * 2021-03-12 2024-03-08 ブリストル-マイヤーズ スクイブ カンパニー Kras g12d阻害剤
JP2024517693A (ja) * 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド 2-アミノベンゾチアゾール化合物及びその使用方法

Also Published As

Publication number Publication date
WO2022232331A1 (en) 2022-11-03
EP4329757A4 (en) 2025-03-26
MX2023012726A (es) 2024-01-04
CA3217856A1 (en) 2022-11-03
EP4329757A1 (en) 2024-03-06
US20250059205A1 (en) 2025-02-20
AU2022264784A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
US20250059205A1 (en) Heterocyclic Compounds and Methods of Use
EP4479398A1 (en) Quinazoline compounds and use thereof as inhibtors of mutant kras proteins
JP7654071B2 (ja) 複素環スピロ化合物及び使用方法
JP2024532735A (ja) 複素環式化合物及び使用方法
JP2024532733A (ja) 複素環式化合物及び使用方法
JP2024517693A (ja) 2-アミノベンゾチアゾール化合物及びその使用方法
JP2024532734A (ja) 複素環式化合物及び使用方法
JP2025508702A (ja) キナゾリン化合物、及び変異krasタンパク質の阻害剤としてのその使用
AU2023477424A1 (en) Indazole containing compounds and methods of use
WO2025194057A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
WO2023097194A2 (en) Therapeutic compounds and methods of use
WO2025230862A1 (en) Macrocyclic amino compounds as modulators of kras and uses therof
WO2025230878A1 (en) Macrocyclic compounds as modulators of kras and uses thereof
CN117561063A (zh) 杂环化合物及使用方法
CN117897159A (zh) 杂环化合物及使用方法
CN117835976A (zh) 杂环化合物及使用方法
CN117881397A (zh) 杂环化合物及使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250425

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260428

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260803